Hot Investor Mandate: Large Healthcare Company Invests Up to $10M in North America or China-Based Life Science Companies in Oncology, CNS, Women’s Health, and More

7 Jul

A fully integrated healthcare solution provider headquartered in China is leading in several market segments in Asia, including family planning medicines, anesthesia, medicines for central nervous system, bio-medicines and others. The group is seeking in-licensing, acquisition, and partnership opportunities based in China and North America. For early stage assets, allocation sizes can be flexible, ranging from $2-10M per deal. The group can either lead or co-invest in a financing round. The firm prefers companies with a China angle and seeks distribution rights in the Chinese market; however this is not a prerequisite criterion.

The firm considers a wide range of technology sectors including therapeutics, medical devices, diagnostics, and healthcare IT. In therapeutics, the group is interested in small molecules, biologics, cell and gene therapies, and biosimilars for oncology, women’s health, CNS, pain management, and infectious diseases. The group seeks assets from preclinical stage to proof-of-concept phase 1. In medical devices, the firm prefers 510K and low-risk devices.

The firm is looking for companies with a complete management team formed by devoted and trustworthy members with domain expertise. The group typically seeks board representation after investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: